Position in LLY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$20,778,927
+$2,630,026 QoQ
Shares Held
17,324
-12.2% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.37%
of 13F equity value
Holder Rank
#871
of 4,605 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 54%
Shared 0%
None 46%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $85,405,719 across 10 Drug Manufacturers - General names. LLY ranks #1 (24.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
17,324 | $20,778,927 | |
| 2 | ABBV |
AbbVie Inc.
|
64,782 | $16,301,742 | |
| 3 | JNJ |
Johnson & Johnson
|
53,762 | $13,653,935 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
90,643 | $11,451,836 | |
| 5 | MRK |
Merck & Co., Inc.
|
74,733 | $9,603,190 | |
| 6 | AZN |
Astrazeneca PLC
|
29,684 | $5,628,680 | |
| 7 | AMGN |
Amgen Inc
|
6,130 | $2,219,795 | |
| 8 | BIIB |
Biogen Inc.
|
10,098 | $2,181,773 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20,778,927 | 17,324 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $18,148,901 | 19,732 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $22,740,230 | 21,160 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $22,468,824 | 29,448 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $28,245,490 | 36,234 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $35,728,040 | 43,259 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $31,922,972 | 41,351 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $31,309,119 | 35,340 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $28,981,213 | 32,010 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $17,382,738 | 22,344 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||